TABLE 1.
Patient demographics, cefepime levels, and pharmacokinetic parameters following a 3-min infusion of 2 g of cefepime to intensive care unit patientsa
| Patient | APACHE scorec | CLCR (ml/min) | C12h (μg/ml) | t1/2β (h) | AUC (μg · h/ml) | CL (ml/min) | MRT (h) | VSS (liter) |
|---|---|---|---|---|---|---|---|---|
| 1b | 24 | 54.0 | 19.7 | 5.6 (0.3) | 690 (22) | 48 (2) | 7.6 (0.4) | 22.0 (1.0) |
| 2 | 10 | 133.8 | 2.6 | 1.8 (0.1) | 239 (12) | 140 (7) | 2.0 (0.1) | 17.0 (1.4) |
| 3 | 16 | 103.2 | 5.7 | 2.9 (0.1) | 423 (10) | 79 (2) | 3.9 (0.1) | 18.4 (0.6) |
| 4b | 15 | 67.2 | 9.6 | 4.7 (0.3) | 396 (13) | 84 (3) | 6.2 (0.4) | 31.4 (1.6) |
| 5 | 11 | 157.2 | 1.1 | 1.5 (0.1) | 226 (9) | 148 (6) | 1.7 (0.1) | 15.0 (0.9) |
| 6 | 9 | 153.6 | 1.6 | 2.3 (0.1) | 199 (12) | 167 (10) | 2.6 (0.1) | 26.4 (2.4) |
| 7 | 9 | 135.6 | 2.1 | 2.5 (0.1) | 241 (9) | 138 (5) | 3.0 (0.1) | 24.6 (1.3) |
| 8b | 14 | 63.6 | 10.0 | 4.0 (0.2) | 467 (14) | 71 (2) | 5.3 (0.2) | 22.8 (1.1) |
| 9 | 15 | 187.2 | 1.6 | 2.2 (0.1) | 257 (8) | 130 (4) | 2.6 (0.1) | 20.2 (0.9) |
| 10 | 11 | 117.6 | 1.1 | 1.9 (0.1) | 285 (11) | 117 (4) | 2.3 (0.1) | 16.2 (0.8) |
| 11 | 8 | 97.2 | 6.3 | 3.5 (0.2) | 337 (12) | 99 (4) | 4.4 (0.2) | 26.3 (1.7) |
| 12 | 8 | 141.0 | 1.6 | 2.3 (0.1) | 194 (9) | 172 (8) | 2.9 (0.1) | 29.8 (2.0) |
| 13 | 13 | 79.8 | 8.5 | 3.8 (0.1) | 424 (10) | 79 (2) | 5.1 (0.2) | 24.0 (0.9) |
| Mediand | 10.5 | 134.7 | 1.9 | 2.5 | 249 | 134 | 2.8 | 22.1 |
| Meand | 11.0 | 130.6 | 3.2 | 3.0 | 283 | 127 | 3.1 | 21.8 |
| SDd | 2.8 | 32.0 | 2.6 | 1.2 | 85 | 33 | 1.1 | 5.1 |
a
CLCR, creatinine clearance; C12h, cefepime concentration at 12 h postdose; t1/2β, elimination half-life; AUC, area under the plasma cefepime concentration-time curve; CL, cefepime clearance; MRT, mean residence time; VSS, apparent volume at steady state. Values shown are estimates, and their standard errors are shown in parentheses.
b
Patient nonevaluable.
c
APACHE score at time of initial cefepime dose.
d
Only data for evaluable patients are included in these statistical results.